Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
Status:
Completed
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
To determine if the addition of midostaurin (PKC412) to Standard of Care (SOC) therapy
reduces relapse in FLT3-ITD mutated AML patients receiving an allogenetic hematopoietic stem
cell transplant,